For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

UNITED THERAPEUTICS RECEIVES SUPPLEMENTAL INFORMATION REQUEST FROM FRENCH AGENCY

Research Triangle Park, NC and Silver Spring, MD, January 6, 2004: United Therapeutics Corporation (NASDAQ: UTHR) announced today that the French regulatory agency, AFSSAPS, has issued an action letter for Remodulin® (treprostinil sodium) Injection requesting supplementary information.

"We view the letter from the French Agence, which followed a meeting in Paris, as a positive step toward approval in France," said Roger A. Jeffs, Ph.D., President and Chief Operating Officer of United Therapeutics. "We are pleased to have had the opportunity to discuss Remodulin in person and will provide the requested supplemental information, including revised labeling, within the 90 days they requested. We remain fully committed to marketing approval in France and Europe."

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

In addition to historical information, this press release contains forward-looking statements about expectations regarding marketing approval of Remodulin in France and Europe which are based on United Therapeutics' beliefs and expectations as to future outcomes. These expectations are subject to risks and uncertainties such as those described in United Therapeutics' periodic reports filed with the Securities and Exchange Commission which may cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in United Therapeutics' periodic reports and documents filed with the Securities and Exchange Commission, including the company's most recent Form 10-K and Form 10-Q. United Therapeutics is providing this information as of January 6, 2004 and undertakes no obligation to publicly update or revise the information contained in this press release whether as a result of new information, future events or any other reason.